Application of biologic agents in the treatment of bullous pemphigoid
- VernacularTitle:生物制剂在大疱性类天疱疮治疗中的应用
- Author:
Tong ZHOU
1
;
Songmei GENG
Author Information
- Keywords: Pemphigoid, bullous; Biologic agent; Treatment; Clinical trial; Rituximab; Omalizumab
- From: Chinese Journal of Dermatology 2023;56(8):789-793
- CountryChina
- Language:Chinese
- Abstract: In recent years, new therapeutic targets for bullous pemphigoid (BP) have continued to emerge, and new biologic agents targeting pathogenic antibodies, complements, T helper type 2 (Th2) and Th17 cytokines in BP have also successively entered clinical trials, e.g., the CD20-targeting antibody rituximab and the IgE-targeting antibody omalizumab have been applied in clinical practice and have benefited some patients with refractory BP. This review summarizes the literature and clinical trials related to biologic agents as the treatment strategy for BP, analyzes and discusses clinical application of new biological agents in BP, in order to provide new ideas for the treatment of refractory BP.
